Professor Kenneth Aldape
Senior Scientist, Princess Margaret Cancer Centre,
Toronto, Ontario, Canada
Kenneth Aldape is a neuropathologist with interest and expertise and surgical neuropathology, especially the diagnosis of tumours of the brain and spinal cord. He trained at the University of California, San Francisco, where he did a residency in anatomic pathology, a fellowship in neuropathology and stayed on as faculty for 6 years. He was most recently professor and department chair of Pathology at the MD Anderson Cancer Centre in Houston, Texas. There he practiced surgical neuropathology and molecular diagnostics, and as department chair, led the effort to bring next-generation sequencing into clinical use at MD Anderson. He was recruited to Toronto to develop a brain tumour program and conduct clinical-translational research in neuro-oncology. He prioritizes investigational work that translates into improvements in diagnosis and outcome which includes the development of new diagnostics for clinical purposes. At UHN, he will prioritize the integration of molecular information into tumor classification for diagnostic and academic purposes where clinically appropriate. Most recently, he is spearheading methylation profiling as a resource for UHN molecular diagnostics, where it has the potential to serve as a resource across subspecialties and tumor types to classify and subtype specific tumor entities. He has over 350 peer-reviewed publications, as well as a number of grants and awards. He is a senior editor of the journal Neuro-Oncology, a recognized resource in the field (impact factor=6.8). He is recognized as a neuropathology consultant in a number or forums, and is the neuropathology reviewer for several national and international clinical trials in glioma. He is an active participant and member of the WHO panel developing updated guidelines for the classification of brain tumours ("WHO blue book"), where the recent update integrates molecular information into the classification of specific tumor entities.